Posted by Michael Wonder on 12 Jan 2026
PHARMAC funds treatment for rare disorders
12 January 2026 - PHARMAC will fund nitisinone for people with the rare disorders tyrosinaemia type 1 and alkaptonuria from 1 February 2026.
Nitisinone is currently funded through Pharmac’s Named Patient Pharmaceutical Assessment policy. From February, it will be listed on the Pharmaceutical Schedule, making it easier for clinicians to prescribe and for people to access treatment.
